Design of Liposome Formulations for CRISPR/Cas9 Enzyme Immobilization: Evaluation of 5-Alpha-Reductase Enzyme Knockout for Androgenic Disorders

Akbaba, Hasan; Erel-Akbaba, Gülşah; Başpınar, Yücel; Şentürk, Şerif

doi:10.1021/acsomega.3c07138

ACS Omega

2023

DOI: 10.1021/acsomega.3c07138

|View full text |Cite

Design of Liposome Formulations for CRISPR/Cas9 Enzyme Immobilization: Evaluation of 5-Alpha-Reductase Enzyme Knockout for Androgenic Disorders

Hasan Akbaba,

Gülşah Erel-Akbaba,

Yücel Başpınar

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

2025

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 78 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Rabies virus-mimicking liposomes for targeted gene therapy in Alzheimer’s disease

Erel-Akbaba,

Akbaba,

Karaman

et al. 2025

International Journal of Pharmaceutics

View full text Add to dashboard Cite

Rabies virus-mimicking liposomes for targeted gene therapy in Alzheimer’s disease

Erel-Akbaba,

Akbaba,

Karaman

et al. 2025

International Journal of Pharmaceutics

View full text Add to dashboard Cite

Targeting mRNA-coding genes in prostate cancer using CRISPR/Cas9 technology with a special focus on androgen receptor signaling

Tabibian,

Moghaddam,

Motevaseli

et al. 2024

Cell Commun Signal

View full text Add to dashboard Cite

Background Prostate cancer is among prevalent cancers in men. Numerous strategies have been proposed to intervene with the important prostate cancer-related signaling pathways. Among the most promising strategies is CRISPR/Cas9 strategy. This strategy has been used to modify expression of a number of genes in prostate cancer cells. Aims This review summarizes the most recent progresses in the application of CRISPR/Cas9 strategy in modification of prostate cancer-related phenotypes with an especial focus on pathways related to androgen receptor signaling. Conclusion CRISPR/Cas9 technology has successfully targeted several genes in the prostate cancer cells. Moreover, the efficiency of this technique in reducing tumor burden has been tested in animal models of prostate cancer. Most of targeted genes have been related with the androgen receptor signaling. Targeted modulation of these genes have affected growth of castration-resistant prostate cancer. PI3K/AKT/mTOR signaling and immune response-related genes have been other targets that have been successfully modulated by CRISPR/Cas9 technology in prostate cancer. Based on the rapid translation of this technology into the clinical application, it is anticipated that novel treatments based on this technique change the outcome of this malignancy in future.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Design of Liposome Formulations for CRISPR/Cas9 Enzyme Immobilization: Evaluation of 5-Alpha-Reductase Enzyme Knockout for Androgenic Disorders

Cited by 2 publications

References 78 publications

Rabies virus-mimicking liposomes for targeted gene therapy in Alzheimer’s disease

Rabies virus-mimicking liposomes for targeted gene therapy in Alzheimer’s disease

Targeting mRNA-coding genes in prostate cancer using CRISPR/Cas9 technology with a special focus on androgen receptor signaling

Contact Info

Product

Resources

About